Efficacy and safety of novel multi‐lumen catheter for chronic total occlusions. Issue 3 (4th November 2014)

• Record Type: Journal Article
• Authors: Mitsutake, Yoshiaki; Ebner, Adrian; Yeung, Alan C.; Taber, Mark D.; Davidson, Charles J.; Ikeno, Fumiaki
• Is Part Of: Catheterization and cardiovascular interventions. Volume 85:Issue 3(2015:Feb. 15)
• Page Start: E70
• Page End: E75
• Publication Date: 2014-11-04
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25711
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ccd25711-sec-0001" sec-type="section"> <title>Objective</title> <p>To report our initial animal and human experience with a new multi‐lumen catheter called MultiCross™ (Roxwood Medical, Inc.) in a porcine coronary model and patients with a chronic total occlusion (CTO).</p> </sec> <sec id="ccd25711-sec-0002" sec-type="section"> <title>Methods</title> <p>Preclinical safety study was done in the coronary vasculature of a porcine model. In a clinical setting, patients with a CTO of a coronary artery (<italic>n</italic> = 5) were enrolled. After an initial unsuccessful attempt using a conventional guidewire, operators could use the MultiCross system. The primary efficacy endpoint was successful recanalization (technical success) and the primary safety endpoint was serious adverse events through 30 days post‐procedure.</p> </sec> <sec id="ccd25711-sec-0003" sec-type="section"> <title>Results</title> <p>The MultiCross catheter was used for all patients after failure of the initial attempt with a guidewire. Successful recanalization was achieved in all CTOs attempted (100%). No patients reported any adverse events at 30 days post‐procedure.</p> </sec> <sec id="ccd25711-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In this first‐in‐man experience, the MultiCross catheter has the potential to enhance crossing of CTOs. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>